Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Table 5 Ratio of SCr [the final evaluation point^a/W0 (week 0 of the treatment period)] analyzed by the ANCOVA model

Treatment group	Number of patients	Least square mean of the ratio of SCr		Difference in the least square mean (versus placebo)		P-value^*
Treatment group	Number of patients	Point estimate	SE	Point estimate	SE	P-value^*
Placebo	34	1.169	0.032	–	–	–
120 μg	32	1.069	0.033	0.100	0.045	0.0309
240 μg	36	1.064	0.031	0.105	0.044	0.0204

ISSN: 1471-2369